Agree Realty stands out as a premier net-lease REIT, boasting a high-quality, diversified portfolio anchored by investment-grade, necessity-based retail tenants. ADC's disciplined, multifaceted growth strategy—acquisitions, development, and partner funding—drives superior risk-adjusted returns and justifies its premium valuation. A fortress balance sheet, robust cash flow, and consistent dividend growth position ADC as a resilient, income-focused investment amid market volatility.

Annaly Capital (NLY 0.66%) has a huge dividend yield that approaches 15%. And the mortgage real estate investment trust (REIT) just increased its dividend at the start of 2025.

I have made many mistakes over the years. Some have cost me a lot of money. Learn from my mistakes and avoid major losses.

The Fed is expected to cut interest rates on September 17th, 2025. This could lead to significant upside in the REIT sector. I highlight two REITs that present significant upside potential.

Recent stock price pullbacks in two companies present potential buying opportunities for long-term investors, despite no obvious negative news. I emphasize the importance of distinguishing between temporary dips and fundamental business issues, referencing Warren Buffett's advice. T-Mobile's pullback offers a buying opportunity due to strong earnings growth, robust free cash flow, aggressive buybacks, and double-digit dividend increases.

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications.

Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum® are ongoing. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs.

Tariff risks are underappreciated by the market; persistently high tariffs could weigh on economic growth, and investor complacency is unwarranted. Slowing population growth and deportations threaten U.S. economic expansion, especially in labor-dependent sectors, as immigration is key to workforce and consumption growth. Utility-scale renewables remain resilient despite policy headwinds, with cost competitiveness and strong demand from major tech firms supporting continued growth.

When you shift from building a nest egg to living off of your savings in retirement, there may also be a big change in the investment approach you take. Income often becomes more important since leaving the workforce means you need to replace the monthly income stream from your job.

Agree Realty stands out for its disciplined capital allocation, conservative underwriting, and sector-leading balance sheet strength among net lease REITs. ADC prioritizes e-commerce-resistant tenants, maintains high investment-grade exposure, and consistently demonstrates prudent acquisition and disposition strategies. The company's low leverage and minimal near-term debt maturities shield it from interest rate headwinds, supporting reliable AFFO growth and dividend safety.